Solution for infusion 10mg/5ml, 50mg/25ml, 200mg/100ml

Doxorubicin is a cytotoxic medicinal product that is indicated in the following neoplastic conditions:

  • Small-cell lung cancer (SCLC)
  • Breast cancer
  • Recurrent ovarian carcinoma
  • Systemic treatment of local advanced or metastasized bladder carcinoma
  • Intravesical prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection
  • Neoadjuvant and adjuvant therapy of osteosarcoma
  • Advanced soft-tissue sarcoma in adults
  • Ewing’s sarcoma
  • Hodgkin’s disease
  • Non-Hodgkin’s lymphoma
  • Acute lymphatic leukaemia
  • Acute myeloblastic leukaemia
  • Advanced multiple myeloma
  • Advanced or recurrent endometrial carcinoma
  • Wilms’ tumour
  • Advanced papillary/follicular thyroid cancer
  • Anaplastic thyroid cancer
  • Advanced neuroblastoma

Doxorubicin is frequently used in combination chemotherapy regimens with other cytostatic medicinal products.